Compare BioNano Genomics Inc (BNGO) vs HCA Health Inc (HCA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs HCA Health Inc — how do they compare? BioNano Genomics Inc trades at $1.19 (market cap $13.66M), while HCA Health Inc trades at $410.62 (market cap $89.08B). The key difference: HCA Health Inc is far larger — about 6521.2× BioNano Genomics Inc's market cap, and HCA Health Inc pays a 0.76% dividend while BioNano Genomics Inc pays none. Which is the better fit depends on your goals.
| BNGO | HCA | |
|---|---|---|
Market Cap | $13.66M | $89.08B |
Sector | Health | Health |
52-Week High | $4.92 | $545.13 |
52-Week Low | $1.06 | $361.32 |
Enterprise Value | $16.26M | $139.62B |
Dividend Yield | — | 0.76% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BNGO trades at $1.16 with a bullish technical signal supported by moving averages. The company shows improving financial trends with narrowing losses and consistent earnings beats, though it remains unprofitable with negative margins. Recent news highlights operational progress including debt retirement and scientific publications. Valuation ratios appear attractive with P/S of 0.31 and P/B of 0.36.
The outlook remains speculative given persistent losses, but improving cash flow trends and analyst optimism provide catalysts. Key risks include ongoing negative profitability and competitive pressures in genomics. With 57% analyst buy ratings and bullish technical momentum, the stock offers high-risk growth potential for investors comfortable with biotech volatility.
HCA Healthcare trades at $414.03, up 0.16% today, with strong technical momentum as price sits above key support levels. The company demonstrates solid fundamentals with Q2 2026 earnings beating estimates, revenue growth to $75.6B in 2025, and consistent dividend payments. Recent management appointments signal strategic focus on clinical operations and ambulatory services.
HCA presents a compelling investment case with attractive valuation (P/E 13.8), analyst consensus price target of $449.93 (8.7% upside), and strong institutional support. However, risks include ongoing legal investigations, rising expenses impacting margins, and high debt levels at 80.9% debt-to-asset ratio that could constrain financial flexibility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About HCA Health Inc
HCA Healthcare is a Nashville-based healthcare provider organization operating the largest collection of acute-care hospitals in the U.S. As of December 2021, the firm owned and operated 182 hospitals, 125 freestanding outpatient surgery centers, and a broad network of physician offices, urgent care clinics, and freestanding emergency rooms across nearly 20 states and a small foothold in England.
Read more on HCA →
